News

Newsletters | STAT

Market 72/100How we got 72/100Source tierEstablished referenceTier ceiling72/100Independent sourcesnot recordedPublished score72/100Scored at the ceiling for a established reference source — it cannot go higher. The number is the source page’s own score, hard-capped at the tier ceiling; corroboration is recorded but cannot lift a score past that cap. Under 40 a claim goes to review instead of publication. Full methodology →
July 28, 2026↗ source

This article is a collection of STAT Plus newsletter headlines that highlights the competitive landscape of obesity drugs. It references the development of triple hormone receptor agonists and monthly formulations for obesity treatment. The content also covers the latest data and news regarding GLP-1 receptor agonists presented at the American Diabetes Association (ADA) conference.

Related peptides

GLP-1 receptor agonistsGLP-1GlucagonGLP-1 receptor agonistGLP-1 drugsGLP-1R
We summarize, we don't invent — every detail here traces to a real, linked source, and the badge reflects how trustworthy that source is. Read the original and decide for yourself.